Spero Therapeutics (SPRO) Return on Invested Capital (2023 - 2025)
Historic Return on Invested Capital for Spero Therapeutics (SPRO) over the last 3 years, with Q3 2025 value amounting to 1.59%.
- Spero Therapeutics' Return on Invested Capital fell 16200.0% to 1.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.59%, marking a year-over-year decrease of 16200.0%. This contributed to the annual value of 0.25% for FY2023, which is N/A changed from last year.
- Latest data reveals that Spero Therapeutics reported Return on Invested Capital of 1.59% as of Q3 2025, which was down 16200.0% from 1.36% recorded in Q4 2024.
- Spero Therapeutics' Return on Invested Capital's 5-year high stood at 0.29% during Q4 2023, with a 5-year trough of 1.59% in Q3 2025.
- Over the past 3 years, Spero Therapeutics' median Return on Invested Capital value was 0.67% (recorded in 2024), while the average stood at 0.66%.
- In the last 5 years, Spero Therapeutics' Return on Invested Capital plummeted by -16500bps in 2024 and then plummeted by -16200bps in 2025.
- Quarter analysis of 3 years shows Spero Therapeutics' Return on Invested Capital stood at 0.29% in 2023, then crashed by -573bps to 1.36% in 2024, then dropped by -17bps to 1.59% in 2025.
- Its last three reported values are 1.59% in Q3 2025, 1.36% for Q4 2024, and 0.02% during Q3 2024.